Related Blog Posts
Pfizer caught in yet more science fraud: Company altered study findings for Neurontin drug
20 hours ago ago from Beyond The Curtain
(NaturalNews) Research into internal company documents has revealed that Pfizer Inc., the world's largest research-based pharmaceutical company, tampered with the results of at least 16 study reports about its epilepsy drug, Neurontin. In order to expand the market for the drug, Pfizer unlawfully removed, altered, and changed published study findings that revealed unfavorable results. Of the 20 study reports that were produced, ...
Related contentPfizer caught.. Again
18 hours ago ago from Jmbblog. The Home of the Wellness and Wealth Warrior. Rated # 1 in defending consumers rights.
Research into internal company documents has revealed that Pfizer Inc., the world's largest research-based pharmaceutical company, tampered with the results of at least 16 study reports about its epilepsy drug, Neurontin. In order to expand the market for the drug, Pfizer unlawfully removed, altered, and changed published study findings that revealed unfavorable results. Of the 20 study reports that were produced, eight of them were not ...
Related contentRelated News
Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
21 hours ago ago from Good News Now
SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. "The efficacy and safety data from the Tulip PETAL Study are consistent with what ...
Related contentNorthwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
6 hours ago ago from PopEater
BETHESDA, Md., Dec. 10 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) announced today that Robert A. Farmer has joined the company's Board of Directors. Mr. Farmer, a graduate of Dartmouth College and Harvard Law School, currently serves on six other corporate boards. Mr. Farmer served as the national treasurer of four presidential campaigns, including those of John Kerry, Bill ...
Related contentLilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
7 hours ago ago from PopEater
NEW YORK, Dec. 10 /PRNewswire-FirstCall/ -- -- Company remains focused on speeding innovation to patients and delivering greater value to customers. -- Five strategic business units prepared to maximize growth opportunities in multiple therapeutic areas and geographies. -- Lilly advances ranking to ninth in worldwide pharmaceutical sales; fastest growing top 10 pharma company in the U.S., major Europe and globally. -- R&D pipeline boasts more ...
Related contentBiodel Reports Fourth Quarter and Fiscal Year 2009 Financial Results
7 hours ago ago from PopEater
Biodel Inc. (Nasdaq: BIOD) today reported financial results for the fourth quarter and fiscal year ended September 30, 2009. Fourth Quarter and Fiscal Year 2009 Financial Results Biodel reported a net loss for the quarter ended September 30, 2009 of $10.5 million, or $0.44 per share, compared to a net loss of $12.7 million, or $0.53 per share, for the fourth quarter of fiscal year 2008. Net loss applicable to common stockholders for the year ...
Related contentRelated Videos
Nothing to see... move along.
